Opexa Therapeutics shrinks net loss in 2006
Houston Business Journal - Houston,TX,USA
In November, Opexa (NASDAQ: OPXA) initiated a Phase IIb trial in multiple sclerosis with its lead drug candidate, Tovaxin. ...
See all stories on this topic

Opexa Reports Year End 2006 Financial Results
Business Wire (press release) - San Francisco,CA,USA
The increase was primarily due to the costs of the clinical trials for Tovaxin and research and development in support of pre-clinical diabetes stem cell ...
See all stories on this topic